These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 19168190)

  • 1. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
    Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
    J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study.
    Horakova D; Cox JL; Havrdova E; Hussein S; Dolezal O; Cookfair D; Dwyer MG; Seidl Z; Bergsland N; Vaneckova M; Zivadinov R
    J Neurol Neurosurg Psychiatry; 2008 Apr; 79(4):407-14. PubMed ID: 17550987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
    Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
    Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
    Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study.
    Oreja-Guevara C; Rovaris M; Iannucci G; Valsasina P; Caputo D; Cavarretta R; Sormani MP; Ferrante P; Comi G; Filippi M
    Arch Neurol; 2005 Apr; 62(4):578-84. PubMed ID: 15824256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.
    Tedeschi G; Dinacci D; Comerci M; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Patti F; Morra VB; Servillo G; Orefice G; Paciello M; Prinster A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Brunetti A; Salemi G; D'Amelio M; Simone I; Salvatore M; Bonavita V; Alfano B
    Mult Scler; 2009 Feb; 15(2):204-11. PubMed ID: 18987104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study.
    Dolezal O; Gabelic T; Horakova D; Bergsland N; Dwyer MG; Seidl Z; Krasensky J; Ramasamy DP; Vaneckova M; Havrdova E; Zivadinov R
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S42-8. PubMed ID: 24321154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain atrophy and lesion load in a large population of patients with multiple sclerosis.
    Tedeschi G; Lavorgna L; Russo P; Prinster A; Dinacci D; Savettieri G; Quattrone A; Livrea P; Messina C; Reggio A; Bresciamorra V; Orefice G; Paciello M; Brunetti A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Patti F; Salemi G; Cammarata E; Simone IL; Salvatore M; Bonavita V; Alfano B
    Neurology; 2005 Jul; 65(2):280-5. PubMed ID: 16043800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3T deep gray matter T2 hypointensity correlates with disability over time in stable relapsing-remitting multiple sclerosis: a 3-year pilot study.
    Zhang Y; Metz LM; Yong VW; Mitchell JR
    J Neurol Sci; 2010 Oct; 297(1-2):76-81. PubMed ID: 20708201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for progressive gray matter loss in patients with relapsing-remitting MS.
    Valsasina P; Benedetti B; Rovaris M; Sormani MP; Comi G; Filippi M
    Neurology; 2005 Oct; 65(7):1126-8. PubMed ID: 16217074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis.
    Battaglini M; Giorgio A; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
    J Neurol Sci; 2009 Jul; 282(1-2):55-60. PubMed ID: 19286193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
    Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
    J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.
    Rovaris M; Agosta F; Sormani MP; Inglese M; Martinelli V; Comi G; Filippi M
    Brain; 2003 Oct; 126(Pt 10):2323-32. PubMed ID: 12937086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis - A longitudinal voxel-based morphometry study.
    Bendfeldt K; Kuster P; Traud S; Egger H; Winklhofer S; Mueller-Lenke N; Naegelin Y; Gass A; Kappos L; Matthews PM; Nichols TE; Radue EW; Borgwardt SJ
    Neuroimage; 2009 Mar; 45(1):60-7. PubMed ID: 19013533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study.
    Calabrese M; Rocca MA; Atzori M; Mattisi I; Bernardi V; Favaretto A; Barachino L; Romualdi C; Rinaldi L; Perini P; Gallo P; Filippi M
    Neurology; 2009 Apr; 72(15):1330-6. PubMed ID: 19365054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender-related differences in MS: a study of conventional and nonconventional MRI measures.
    Antulov R; Weinstock-Guttman B; Cox JL; Hussein S; Durfee J; Caiola C; Dwyer MG; Bergsland N; Abdelrahman N; Stosic M; Hojnacki D; Munschauer FE; Miletic D; Zivadinov R
    Mult Scler; 2009 Mar; 15(3):345-54. PubMed ID: 19028830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA.
    Paolillo A; Piattella MC; Pantano P; Di Legge S; Caramia F; Russo P; Lenzi GL; Pozzilli C
    J Neurol; 2004 Apr; 251(4):432-9. PubMed ID: 15083288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.